Five Prime Therapeutics, Inc. (FPRX) Social Stream



Five Prime Therapeutics, Inc. (FPRX): $38.00

0.01 (+0.03%)

POWR Rating

Component Grades

Momentum

D

Stability

F

Sentiment

Quality

D

Add FPRX to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#314 of 493

in industry

Five Prime Therapeutics Inc (FPRX) Price Targets From Analysts

The tables below show the price targets and recommendations analysts covering FPRX.

Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
7 $34 $14 $27 $38 -28.95%

FPRX reports an average of 141.44% for its upside potential over the past 181 days.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2020-05-13 5 11 5 7.60 4.080 86.27%
2020-06-19 5 11 5 8.40 4.395 91.13%
2020-07-22 5 11 5 8.40 6.155 36.47%
2020-09-02 5 11 5 8.40 4.230 98.58%
2020-09-21 6 11 5 8.83 3.830 130.55%
2020-11-10 7 34 14 27.00 5.340 405.62%

FPRX Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs

The Trend in the Broker Recommendations


Over the past 153 days, FPRX's average broker recommendation rating improved by 0.14.

The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.

  • Five Prime Therapeutics Inc's upside potential (average analyst target price relative to current price) is greater than 5.33% of all US stocks.
  • The variance in analysts' estimates of FPRX is lower than 11.36% of stocks in the small market cap category.
  • The number of analysts covering the stock of FPRX is higher than 87.31% of stocks in the small market cap category.
  • The average analyst price target of FPRX is higher than 65.09% of stocks in the small market cap category.

Make investment decisions regarding FPRX using the data that counts. Try POWR Ratings for free.


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!